Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy by Barbour, Sean J, Fervenza, Fernando C, Induruwage, Dilshani, Brenchley, Paul E, Rovin, Brad, Hladunewich, Michelle A, Reich, Heather N, Lafayette, Richard, Aslam, Nabeel, Appel, Gerald B, Zand, Ladan, Kiryluk, Krzysztof, Liu, Lili, Cattran, Daniel C

Get full text

Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial by Kadatz, Matthew, Klarenbach, Scott, So, Helen, Fervenza, Fernando C, Cattran, Daniel C, Barbour, Sean J

Get full text

Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A2 receptor antibody-positive membranous nephropathy by Surindran, Sheena, Ayalon, Rivka, Hasan, Nazia, Beck, Laurence H., Salant, David J., Barisoni, Laura, Skolnik, Edward Y., Beara-Lasic, Lada

Get full text

E19 Kidney function in genetic stone formers by Milliner, D, Goldfarb, D.S, Beara-Lasic, L, Edvardsson, V, Bergstralh, E, Lieske, J.C, Palsson, R

Get full text

The effect of big endothelin‐1 in the proximal tubule of the rat kidney by Beara‐Lasić, Lada, Knotek, Mladen, Čejvan, Kenan, Jakšić, Ozren, Lasić, Zoran, Skorić, Boško, Brkljačić, Vera, Banfić, Hrvoje

Get full text

Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts by Beara-Lasic, Lada, Cogal, Andrea, Mara, Kristin, Enders, Felicity, Mehta, Ramila A., Haskic, Zejfa, Furth, Susan L., Trachtman, Howard, Scheinman, Steven J., Milliner, Dawn S., Goldfarb, David S., Harris, Peter C., Lieske, John C.

Get full text

Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy by Sethi, Amit, Miao, Jing, Willrich, Maria Alice V, Frinack, Jody L, Cattran, Daniel C, Fervenza, Fernando C

Get full text